Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk?

@article{Yeshayahu2015MedicationinducedDD,
  title={Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk?},
  author={Yonatan Yeshayahu and Dror Koltin and Jill Hamilton and Paul C Nathan and Stacey Urbach},
  journal={Pediatric diabetes},
  year={2015},
  volume={16 2},
  pages={104-8}
}
Medication-induced diabetes (MID) is seen in children treated for acute lymphoblastic leukemia (ALL) mostly during induction, due to the use of l-asparaginase and glucocorticoids. Our objective was to assess whether MID during induction, is a risk factor for future impaired glucose tolerance (IGT), diabetes, or metabolic syndrome. Ninety survivors of… CONTINUE READING